Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Aimee J. Guerrero"'
Autor:
Alejandro M. S. Mayer, Aimee J. Guerrero, Abimael D. Rodríguez, Orazio Taglialatela-Scafati, Fumiaki Nakamura, Nobuhiro Fusetani
Publikováno v:
Marine Drugs, Vol 19, Iss 2, p 49 (2021)
The review of the 2016–2017 marine pharmacology literature was prepared in a manner similar as the 10 prior reviews of this series. Preclinical marine pharmacology research during 2016–2017 assessed 313 marine compounds with novel pharmacology re
Externí odkaz:
https://doaj.org/article/a5aeb3bbc3bb45ec859644834af27738
Publikováno v:
Drugs in Context, Vol 7, Pp 1-15 (2018)
A review of literature published regarding non-tenofovir antiretroviral agents causing renal adverse effects was conducted. The literature involving renal adverse effects and antiretroviral therapy is most robust with protease inhibitors, specificall
Externí odkaz:
https://doaj.org/article/9267c4ad9fa741ffa5b26256d468c078
Autor:
Fumiaki Nakamura, Orazio Taglialatela-Scafati, Abimael D. Rodríguez, Alejandro M. S. Mayer, Aimee J Guerrero, Nobuhiro Fusetani
Publikováno v:
Marine Drugs, Vol 19, Iss 49, p 49 (2021)
Marine Drugs
Marine Drugs
The review of the 2016–2017 marine pharmacology literature was prepared in a manner similar as the 10 prior reviews of this series. Preclinical marine pharmacology research during 2016–2017 assessed 313 marine compounds with novel pharmacology re
Autor:
Orazio Taglialatela-Scafati, Aimee J Guerrero, Abimael D. Rodríguez, Nobuhiro Fusetani, Fumiaki Nakamura, Alejandro M. S. Mayer
Publikováno v:
Marine Drugs
The systematic review of the marine pharmacology literature from 2014 to 2015 was completed in a manner consistent with the 1998–2013 reviews of this series. Research in marine pharmacology during 2014–2015, which was reported by investigators in
Publikováno v:
Drugs in Context, Vol 7, Pp 1-15 (2018)
Drugs in Context
Drugs in Context
A review of literature published regarding non-tenofovir antiretroviral agents causing renal adverse effects was conducted. The literature involving renal adverse effects and antiretroviral therapy is most robust with protease inhibitors, specificall